PRP vs. Dextrose Prolotherapy for Sacroiliac Joint Pain: What Does the Evidence Show?
Published November 16, 2026
Protocol: 7 steps in this guide
Neither has been shown to be better than the other. A 2025 international multispecialty guideline on sacroiliac joint complex pain rates the evidence for both as Grade C, low certainty: platelet-rich plasma (PRP) “may be effective” at 3 months, and dextrose prolotherapy “may be effective” at 6 months. The trials it describes compare each treatment with a corticosteroid injection, not with each other, and the two PRP trials point in opposite directions. On current evidence the answer is uncertainty, not a winner.
The sacroiliac joint complex
The sacroiliac (SI) joints connect the base of the spine to the pelvis. The 2025 guideline in Pain Medicine, Consensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group, uses the term “SIJ complex” for the joint and its surrounding structures. SI joint pain is a different source of low back pain from the lumbar facet joints; that comparison is covered in PRP vs. corticosteroid injections for lumbar facet joint pain. Gluteal tendon pain on the outer hip is another separate problem, covered in PRP vs. exercise therapy for gluteal tendinopathy.
Confirming the SI joint as the source
Because the SI joint has to be identified as the pain source, trials select patients in different ways, and that affects results. In the trials the guideline describes, some selected patients by a diagnostic numbing injection into the SI joint, with relief of 50% or 80% required, while one selected patients by three or more positive physical provocation tests without a diagnostic injection. Different selection methods enroll different patients.
PRP: two trials, opposite results
The guideline describes two randomized trials comparing PRP with a corticosteroid injection:
| Trial | Patients | Result |
|---|---|---|
| Chen and colleagues | 26 (15 PRP, 11 steroid), selected by at least 80% relief after a diagnostic injection | Steroid group had lower pain at all time points; 50% responders, steroid vs PRP, 80% vs 21% at 1 month and 70% vs 21% at 3 months; not significant at 6 months (67% vs 25%) |
| Singla and colleagues (2017) | 40 (20 PRP, 20 steroid), selected by provocation tests | PRP group had lower pain at 6 and 12 weeks; 50% responders, PRP vs steroid, 90% vs 25% at 12 weeks |
The guideline notes that the Singla results ran contrary to those of Chen and colleagues. Its conclusion: “Platelet-rich plasma may be effective for the treatment of SIJ complex pain at 3 months post-procedure; Grade C evidence, low level of certainty.” How PRP is prepared is covered in how platelet-rich plasma is made from a blood sample.
Dextrose prolotherapy: the rationale and the trial
Prolotherapy here means injecting a concentrated dextrose (sugar) solution; the idea that it prompts a healing response is a proposed mechanism, not a demonstrated one. The guideline describes a 2010 randomized trial by Kim and colleagues in 48 patients comparing intra-articular corticosteroid with 25% dextrose prolotherapy. Responder rates for 50% pain improvement were higher with prolotherapy: 64% vs 27% at 6 months, and 59% vs 10% at both 10 and 15 months after treatment. The guideline adds a caution: “the average number of study injections was significantly higher among the 23 prolotherapy patients.” Its conclusion: “Dextrose-based prolotherapy may be effective for SIJ complex pain 6 months post-procedure; Grade C evidence, low level of certainty.”
What Grade C means here
The guideline’s summary puts it in one line: “There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief.” Grade C, low certainty, means future studies could change the picture. The same guideline finds “insufficient evidence” for several other injected treatments, including other orthobiologics and non-dextrose prolotherapy.
Why the data cannot name a winner
| Question | What the evidence in the guideline offers |
|---|---|
| PRP vs corticosteroid | Two small trials with opposite results |
| Dextrose vs corticosteroid | One trial favoring dextrose, with more injections in that group |
| PRP vs dextrose | Compared here only indirectly, through different steroid-controlled trials |
| Certainty | Grade C, low, for both |
Ranking PRP against dextrose through separate trials with different patients, selection methods, injection numbers and follow-up times would be guesswork. Why trial design matters is explained in the difference between a placebo-controlled trial and an observational study.
Risks and the broader plan
Any injection into the SI joint carries procedure risks, and blood-thinning medicines should be discussed with the prescriber beforehand. A 2024 multispecialty guideline in the Journal of Pain Research, Evidence-Based Clinical Practice Guidelines on Regenerative Medicine Treatment for Chronic Pain, covers general safety of injectable biologics. Injections are one part of care that can also include physical therapy and other treatments; PRP risks are covered in the main risks of a PRP injection.
For sacroiliac joint pain, a 2025 multispecialty guideline rates both PRP and dextrose prolotherapy as possibly effective on low-certainty evidence, and with no direct comparison between them and conflicting PRP trials, neither can be called the better choice.
Cells linked to this one
This guide leads on to
- H8 PRP vs. Corticosteroid Injections for Lumbar Facet Joint Pain: What Do Trials Show?
- H3 PRP vs. Exercise Therapy for Gluteal Tendinopathy: What Does Research Show?
- B1 How Is Platelet-Rich Plasma Made From a Blood Sample?
- I8 What Is the Difference Between a Placebo-Controlled Trial and an Observational Study?
- B10 What Are the Main Risks of a PRP Injection?
Add a remark